SCID-Xl is catastrophic immunodeficiency disorder caused by mutations within the common gamma chain (?c) gene. While stem cell transplantation using a matched sibling donor can be curative, most patients lack optimal donors leading to poorer outcomes. Gene replacement has many theoretical advantages as an alternative therapeutic approach for SCID-Xl;and pioneering clinical studies using gammaretroviral ?c delivery lead to both significant benefit as well as unanticipated adverse events due to viral enhancer triggered leukemogenesis. The overarching hypothesis of this PPG is that both the efficacy and safety of ?c gene delivery can be significantly improved using recombinant foamy virus (FV) based vectors. Studies in Project 1 are designed to test the hypotheses that yc FV vectors devoid of viral enhancers (with or without additional enhancer blocking elements flanking the transcriptional cassette) will exhibit levels of transgene expression sufficient for functional rescue in vivo while concurrently showing reduced genotoxicity.
The aims of Project 1 are designed to test these hypotheses via detailed phenotypic, functional, and molecular analysis in both: 1) a small animal model of SCID-Xl and 2) hematopoietic stem cells (HSC) derived from SCID-Xl patients. Our specific studies will include efficacy and safety assessment of 1) EFIa-hu-?c FV vectors in vivo in myeloablated vs. non-myeloablated murine SCID-Xl recipients;and in alternative in vitro transactivation assays;2) Preclinical and GMP-grade 1st generation ?c FV in transduced SCID-Xl patient CD34* BM cells;and 3) Candidate insulated 2nd generation ?c FV vectors in HSC from SCID-Xl mice and human patients. Project 1 will utilize all 4 Cores and will interface on multiple levels with work within both Projects 2 and 3. In conjunction with data derived from Projects 2 and 3, our studies will provide key data regarding efficacy, safety and optimal vector design for future 1st and 2nd generation SCID-Xl FV vector clinical trials.
|Everson, Elizabeth M; Trobridge, Grant D (2016) Retroviral vector interactions with hematopoietic cells. Curr Opin Virol 21:41-46|
|Bii, Victor M; Trobridge, Grant D (2016) Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers (Basel) 8:|
|Everson, Elizabeth M; Olzsko, Miles E; Leap, David J et al. (2016) A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance. Mol Ther Methods Clin Dev 3:16048|
|Hocum, Jonah D; Linde, Ian; Rae, Dustin T et al. (2016) Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes. Sci Rep 6:36610|
|Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173|
|Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46|
|Browning, Diana L; Collins, Casey P; Hocum, Jonah D et al. (2016) Insulated Foamy Viral Vectors. Hum Gene Ther 27:255-66|
|Rae, Dustin T; Collins, Casey P; Hocum, Jonah D et al. (2015) Modified Genomic Sequencing PCR Using the MiSeq Platform to Identify Retroviral Integration Sites. Hum Gene Ther Methods 26:221-7|
|Felsburg, Peter J; De Ravin, Suk See; Malech, Harry L et al. (2015) Gene therapy studies in a canine model of X-linked severe combined immunodeficiency. Hum Gene Ther Clin Dev 26:50-6|
|Gori, Jennifer L; Butler, Jason M; Chan, Yan-Yi et al. (2015) Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells. J Clin Invest 125:1243-54|
Showing the most recent 10 out of 35 publications